Skip to main content

Shawver Laura's Form 4 filing

ARS Pharmaceuticals, Inc. (SPRY) · filed Mar 7, 2025

Accession no.
0001415889-25-007438
Filed
Mar 7, 2025
Trade date
Mar 5-6, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $560.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shawver LauraCIK 0001551891Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 5, 2025Common StockMOption exerciseAcquired+400$4.85+$1,940210,746Direct
Mar 5, 2025Common StockSSaleDisposed−400$11.00−$4,400210,346Direct
Mar 6, 2025Common StockMOption exerciseAcquired+49,600$4.85+$240,560259,946Direct
Mar 6, 2025Common StockSSaleDisposed−49,600$11.21−$556,016210,346Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 5, 2025Common StockMOption exerciseDisposed−400$0.00$0123,664Direct
Mar 6, 2025Common StockMOption exerciseDisposed−49,600$0.00$074,064Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)